Evaluation of Efficacy and Safety of Autologous MSCs Combined to Biomaterials to Enhance Bone Healing

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-05-31

Study Completion Date

2016-02-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Bone grafting is widely used in hospitals to repair injured, aged or diseased skeletal tissue. In Europe, about one million patients encounter a surgical bone reconstruction annually and the numbers are increasing due to our ageing population. Bone grafting intends to facilitate bone healing through osteogenesis (i.e. bone generation) at the site of damage, but this is only attained presently by including cells capable of forming bone into the augmentation.

Bone autograft is the safest and most effective grafting procedure, since it contains patient's own bone growing cells (to enhance osteogenesis) and proteins (to enhance osteoinduction), and it providing a scaffold for the new bone to grow into (osteoconduction). However, bone autograft is limited in quantity (about 20 cc) and its harvesting (e.g. from the iliac crest) represents an additional surgical intervention, with frequent consequent pain and complications.

We hypothesize that using autologous bone marrow cells expanded in GMP facility surgically implanted with synthetic bone substitutes contribute to the resolution of the health and socioeconomic complications of delayed union or non-union after diaphyseal and metaphyseal-diaphyseal fractures with safety and efficacy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of Atrophic Nonunion Fractures by Autologous Mesenchymal Stem Cell Percutaneous Grafting

NCT01429012

Nonunion Fracture

WITHDRAWN PHASE2

Treatment of Osteonecrosis of the Femoral Head by Bone Marrow Transplantation

NCT00821470

Necrosis

COMPLETED PHASE1

Effectiveness of Adipose Tissue Derived Mesenchymal Stem Cells as Osteogenic Component in Composite Grafts

NCT01532076

Osteoporotic Fractures

TERMINATED PHASE2

Controlled Study of Stage 3 Osteonecrosis Treatment by Bone Marrow

NCT01544712

Non Traumatic Osteonecrosis of the Femoral Head (Hip)

COMPLETED NA

Autologous Stem Cell Therapy for Fracture Non-union Healing

NCT02177565

Non-union of Fractures

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Tissue engineering combines bone marrow cells or mesenchymal stem cells (MSCs), synthetic scaffolds and molecular signals (growth or differentiating factors) in order to form hybrids constructs. For bone reconstruction purposes, human MSCs have been seeded and cultured on porous calcium phosphate ceramics in osteogenic media. Some clinical studies with low numbers of patients have been reported using this approach but the outcomes were inconsistent with low efficacy in bone regeneration. The reasons of the limited clinical success may be due to several bottlenecks in the multidisciplinary field of bone tissue engineering. The association in vitro of biomaterials and osteoprogenitor cells raises technical challenges and regulatory and ethic issues for the implementation of clinical trials, whereas the expansion of MSCs is now possible in GMP Facility.

The expected results are to obtain bone consolidation thus healing of delayed union or non-union, as proven by imaging techniques, without using bone graft. This will prove the efficacy of the proposed IMP based on pluripotent MSCs expanded in a GMP facility and mixed with granulated biphasic calcium phosphate in the surgical setting before implantation. No expected complications related to the procedure are expected. Changes in serum levels of bone turnover markers will be described.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Delayed Union After Fracture of Humerus, Tibial or Femur

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Implantation surgery

All the patients will have the implantation surgery. This trial is a one-arm study.

Group Type EXPERIMENTAL

Implantation of bone substitute plus autologous cultured mesenchymal cells

Intervention Type PROCEDURE

Implantation surgery of a synthetic bone substitute associated with autologous bone marrow cells expanded

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Implantation of bone substitute plus autologous cultured mesenchymal cells

Implantation surgery of a synthetic bone substitute associated with autologous bone marrow cells expanded

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 to 65, both sexes
* Traumatic isolated closed or open Gustilo I and II humerus, tibial or femur diaphyseal or metaphyseal-diaphyseal fracture status delayed union or non-union
* At least 3 months from acute fracture
* Able to provide informed consent, and signed informed consent
* Patients (by themselves) should have medical health care coverage to be included in a research study
* Able to understand and accept the study constraints

Exclusion Criteria

* Pregnancy, breast feeding women and women who are of childbearing age and not practicing adequate birth control
* Participation in another therapeutic trial in the previous 3 months
* Delayed union or non-union related to iatrogeny
* Segmental bone loss requiring specific therapy (bone transport, large structural allograft, megaprosthesis, etc)
* Vascular or neural injury
* Other fractures causing interference with weight bearing
* Acute persistent chronic bacterial infections such as brucellosis, typhus, leprosy, relapsing fever, melioidosis and tularemia
* Visceral injuries of diseases interfering with callus formation (cranioencephalic trauma, etc.)
* History of bone harvesting on iliac crest contraindicating bone-marrow aspiration
* Corticoid or immunosuppressive therapy more than one week in the three months prior to study inclusion
* History of prior or concurrent diagnosis of HIV-, Syphilis, Hepatitis-B- or Hepatitis-C-infection (confirmed by serology or PCR)
* History of neoplasia or current neoplasia in any organ
* Subject legally protected, under legal guardianship, deprived of their liberty by judicial or administrative decision, subject of psychiatric care, or admission to a health facility.
* Impossibility to meet at the appointments for the follow up
* Insulin dependent diabetes
* Obesity (BMI \> 30)
* Autoimmune inflammatory disease
* Current treatment by biphosphonate or stopped in the three months prior to study inclusion.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No